All In Biotech

Drug Trial Radar · NCT03710434

AZD4635 Relative Bioavailability Study

A Phase I, Open-Label Study to Assess the Pharmacokinetics and Relative Bioavailability of AZD4635 in Non-Smoking Healthy Male Subjects, With the Option to Assess Food Effect, pH Effect and Absolute Bioavailability

Last checked: Nov 19, 2026Latest source record: May 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Nov 1, 2018

Primary completion

Apr 2, 2019

Study completion Apr 2, 2019

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Quotient Sciences
First posted
Oct 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To investigate the pharmacokinetics and relative bioavailability of AZD4635 solid oral formulation and compare with the nano-suspension reference formulation with the option to assess food effect, pH effect and absolute bioavailability

Conditions

  • Healthy Volunteers

Interventions

  • AZD4635 50 mg nano-suspension (reference)Drug

    Subjects will receive a single dose of AZD4635 50 mg nano-suspension (reference) in the fasted state.

  • AZD4635 solid oral formulation - fastedDrug

    Subjects will receive a single dose of AZD4635 solid oral formulation, in the fasted state.

  • AZD4635 solid oral formulation - fedDrug

    Subjects will receive a single dose of AZD4635 solid oral formulation, in the fed state.

  • Lansoprazole and AZD4635 50 mg solid oral formulationDrug

    Subjects will receive lansoprazole 30 mg BID for 5 days followed by a single dose of AZD4635 50 mg solid oral formulation in the fasted state.

  • AZD4635 solid oral formulation variant 1 - fastedDrug

    Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state.

  • AZD4635 solid oral formulation variant 2 - fastedDrug

    Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.

  • [14C] AZD4635 IV microtracer - fastedDrug

    Subjects will receive a single dose of \[14C\] AZD4635 IV microtracer. This intervention will be co-administered with AZD4635 solid oral formulation variant 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma concentration (Cmax) of AZD4635 solid oral formulation and nano-suspension (reference)Time frame: Blood samples collected pre-dose, and postdose at 0.25h, 0.5h, 1h, 1.5h, 2h, 4h, 6h, 8h, 12h, 24h, 48h, 72h, 96h and 120h
  2. Exposure to AZD4635 solid oral formulation and nano-suspension (reference)Time frame: Blood samples collected pre-dose, and postdose at 0.25h, 0.5h, 1h, 1.5h, 2h, 4h, 6h, 8h, 12h, 24h, 48h, 72h, 96h and 120h

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Ruddington, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.